
Opinion|Videos|March 4, 2025
Long-Term Use of Topical Treatments in Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD, Randy Alevi, DO
Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the long-term efficacy and safety profiles of these newer agents compare with topical corticosteroids?
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Healthiest States in America: A 2025 Ranking
2
FDA Clears First At-Home 4-in-1 Respiratory Test Detecting RSV, Influenza A/B, and COVID-19 in Infants, Adults
3
Nationwide Survey Finds Widespread Concern About Topical Steroid Use, Emphasizes Need for Long-Term Management Strategies in Chronic Inflammatory Skin Disease
4





































































































































